Calton & Associates Inc. acquired a new position in shares of Novartis AG (NYSE:NVS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,357 shares of the company’s stock, valued at approximately $118,000.

A number of other hedge funds have also recently bought and sold shares of NVS. Delaney Dennis R increased its position in shares of Novartis by 40.9% in the fourth quarter. Delaney Dennis R now owns 25,285 shares of the company’s stock worth $2,122,000 after purchasing an additional 7,335 shares during the period. Notis McConarty Edward increased its position in shares of Novartis by 11.6% in the fourth quarter. Notis McConarty Edward now owns 39,325 shares of the company’s stock worth $3,300,000 after purchasing an additional 4,100 shares during the period. Puzo Michael J increased its position in shares of Novartis by 23.3% in the fourth quarter. Puzo Michael J now owns 89,764 shares of the company’s stock worth $7,535,000 after purchasing an additional 16,989 shares during the period. Kidder Stephen W increased its position in shares of Novartis by 0.9% in the fourth quarter. Kidder Stephen W now owns 90,097 shares of the company’s stock worth $7,565,000 after purchasing an additional 789 shares during the period. Finally, Dempze Nancy E increased its position in shares of Novartis by 33.8% in the fourth quarter. Dempze Nancy E now owns 23,679 shares of the company’s stock worth $1,987,000 after purchasing an additional 5,983 shares during the period. Hedge funds and other institutional investors own 11.06% of the company’s stock.

NVS has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Novartis from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Leerink Swann raised their price target on Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a research report on Tuesday, October 31st. Nord/LB restated a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. Finally, Bank of America cut Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $85.32.

Shares of Novartis AG (NYSE NVS) opened at $83.60 on Wednesday. The firm has a market capitalization of $218,540.00, a PE ratio of 25.72, a P/E/G ratio of 1.94 and a beta of 0.74. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.91. Novartis AG has a 12 month low of $72.67 and a 12 month high of $94.19.

Novartis (NYSE:NVS) last released its quarterly earnings data on Wednesday, January 24th. The company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.04. The business had revenue of $12.92 billion for the quarter, compared to analyst estimates of $12.65 billion. Novartis had a return on equity of 16.03% and a net margin of 15.69%. Novartis’s revenue was up 4.8% compared to the same quarter last year. During the same period last year, the firm posted $1.14 earnings per share. equities analysts predict that Novartis AG will post 5.36 EPS for the current fiscal year.

WARNING: “Calton & Associates Inc. Acquires Shares of 1,357 Novartis AG (NVS)” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://theolympiareport.com/2018/02/14/calton-associates-inc-acquires-shares-of-1357-novartis-ag-nvs.html.

Novartis Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.